Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab for prevention of chronic migraine in Chinese adults
CTR20192077Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of erenumab in chronic migraine, sponsored by Novartis. Started Oct 2019; status: completed.
02
Drugs
erenumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on CTR20192077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192077.